The period spanning 2025 to 2026 has marked one of the most intense eras of corporate restructuring and workforce reduction in the history of the pharmaceutical and biotechnology sectors. Driven by an impending multi-billion-dollar "patent cliff," the compounding pressures of new pricing legislation (such as the U.S. Inflation Reduction Act), and a strategic pivot toward artificial intelligence and precision oncology, companies across the globe are radically optimizing their operations.
BioSpace counted just over 23,000 employees affected by layoffs in the third quarter of 2025 alone, and cuts continued into mid-2026. This report breaks down the specific strategies and impacts of these layoffs across major global markets.
The Mid-Cap Biotech Contraction (2026)
In 2026, smaller to mid-cap biotech firms continued to face extreme cash-preservation pressures, resulting in highly concentrated "surgical" cuts.
- enGene (50% Reduction): In June 2026, enGene announced a reduction in force of about 50% "to streamline operations and preserve cash to focus on BLA and precommercial activities" for its lead gene therapy, detalimogene voraplasmid, in non-muscle invasive bladder cancer.
- Neumora Therapeutics (35% Reduction): After its depression drug navacaprant failed in Phase 3 trials, Neumora said in June 2026 it would stop developing the drug and cut its headcount by about 35% to align the company with a refocused pipeline.
Big Pharma Overhauls (US & EU Hubs)
The largest pharmaceutical conglomerates utilized sweeping, multi-year initiatives to fundamentally alter their organizational structures, heavily impacting the U.S. and Europe.
- Takeda Pharmaceutical (~4,500 global jobs): Takeda said in May 2026 it would cut about 4,500 jobs in fiscal 2026 as part of a restructuring to centralise corporate functions and reduce costs. A spokesperson said this is less than 10% of its global workforce.
- Bayer (Over 12,000 employees globally): Under chief executive Bill Anderson, Bayer rolled out a new operating model known as "Dynamic Shared Ownership" in January 2024, removing layers of management. By November 2025 Bayer had let go of about 13,500 employees, including around 5,000 managers, according to BioSpace.
- BioNTech (~1,860 jobs): BioNTech's layoffs highlight a strategic pivot rather than a financial crisis. In May 2026 the company said it would close manufacturing sites in Idar-Oberstein, Marburg and Tübingen in Germany and in Singapore, affecting about 1,860 positions, because it expects surplus manufacturing capacity.
Regional Impact Analysis
United States: The Epicenter of Downsizing
The U.S. remains the primary target for cost-cutting. With the highest labor costs and the looming threat of Medicare price negotiations (IRA), companies are actively shrinking their U.S. commercial and R&D footprints through the consolidation of regional offices and massive reductions in sales forces.
Europe (EU): Structural Simplification
European layoffs have been driven by corporate un-layering. Due to stricter European labor laws, these reductions have often taken the form of prolonged, negotiated severance packages, voluntary redundancy schemes, and the strategic non-replacement of retiring staff to reduce administrative bloat.
India: The Growth Anomaly
While the U.S. and EU experience contraction, India is acting as a strategic buffer for global pharma. As companies lay off thousands in high-cost Western headquarters, they are simultaneously expanding their footprint in India. Global giants are heavily investing in Indian Contract Research Organizations (CROs), data analytics centers, and IT hubs. The routine clinical monitoring and data management jobs being eliminated in the West are increasingly being offshored to highly skilled, cost-effective hubs in India.
Correction, 2 November 2026: We replaced an unsourced 2025 job-cut total with a BioSpace figure, and corrected the descriptions of the enGene, Neumora, Takeda, Bayer and BioNTech cuts to match company and news reports, including that BioNTech is closing its Singapore site rather than scrapping an expansion.
